Drug resistance is a very important factor contributing to the failure of current HIV therapies.
The ability to understand the resistance mechanism of HIV-protease mutants may be useful …

A major problem in the antiretroviral treatment of HIV-infections with protease-inhibitors is
the emergence of resistance, resulting from the occurrence of distinct mutations within the …

The V82F/I84V double mutation is considered as the key residue mutation of the HIV-1
protease drug resistance because it can significantly lower the binding affinity of protease …

A major problem in the antiretroviral treatment of HIV-infections with protease-inhibitors is
the emergence of resistance, resulting from the occurrence of distinct mutations within the …

Drug resistant mutations have severely restricted the success of HIV therapy. These
mutations frequently involve the aspartic protease encoded by the virus. Knowledge of the …

Drug resistance of mutations in HIV-1 protease (PR) badly reduce the efficiency of the
current inhibitors in clinical treatments of AIDS. In this work, molecular dynamics (MD) …

Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …

The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with
conventional long-treatment therapies against acquired immunodeficiency syndrome. These …

The PR20 HIV-1 protease, a variant with 20 mutations, exhibits high levels of multi-drug
resistance; however, to date, there has been no report detailing the impact of these 20 …

Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition,
mutations in this protein during the course of patient treatment can render them inefficient …